Industries > Pharma > Antithrombotic Drugs Market 2017-2027

Antithrombotic Drugs Market 2017-2027

Anticoagulants, Antiplatelets, Fibrinolytics

PUBLISHED: 12 July 2017
PAGES: 185
PRODUCT CODE: PHA0211

Clear
WOOCS 2.2.1
SKU: PHA0211 Categories: , ,

Antithrombotic Drugs Market 2017-2027: Anticoagulants, Antiplatelets, Fibrinolytics
The revenue of the antithrombotic drugs market in 2016 is estimated at $18.08bn and is expected to grow at a CAGR of 7.9% in the first half of the forecast period. The anticoagulants segment accounted for the largest share of the market in 2016, this segment held 58.5% of the antithrombotic drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 185-page report you will receive 84 tables and 69 figures – all unavailable elsewhere.

The 185-page report provides clear detailed insight into the antithrombotic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Antithrombotic drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the main submarkets:
• Anticoagulants
• Antiplatelet agents
• Fibrinolytic treatments

This report provides the revenue forecast for these anticoagulant agents:
• Direct factor Xa inhibitors
• Heparins
• Direct thrombin inhibitors
• Vitamin K antagonists

• This report provides the revenue forecast for the leading products in this market:
• Xarelto
• Plavix
• Lovenox
• Eliquis
• Pradaxa
• Activase
• Brilinta/Brilique
• Aspirin Cardio
• Effient
• Aggrenox/Asasantin
• Fragmin
• Pletal
• Angiomax/Angiox
• Rest of Market

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• US
• Germany
• France
• UK
• Italy
• Spain
• Japan
• China
• Brazil
• Russia
• India
• Rest of World

Antithrombotic Drugs Market 2017-2027

• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

• Our study includes SWOT and STEP analysis of the antithrombotic drugs market.

• Our study discusses the selected leading companies that are the major players in the antithrombotic drugs market:
• Bayer
• Bristol Myers Squibb
• Sanofi
• Boehringer-Ingelheim
• Roche (Genentech)
• AstraZeneca
• Eli Lilly
• Pfizer
• Otsuka Pharmaceutical
• The Medicines Company

Visiongain’s study is intended for anyone requiring commercial analyses for the antithrombotic drugs market. You find data, trends and predictions.

Buy our report today Antithrombotic Drugs Market 2017-2027: Anticoagulants, Antiplatelets, Fibrinolytics.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Antithrombotic Drugs Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Antithrombotic Drugs Market 2017-2027


Latest Pharma news

Visiongain Publishes Pharmaceutical Product Information Management System Market Report 2020-2030

Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.

19 October 2020

READ

Visiongain Publishes Pulmonary/Respiratory Drug Delivery Market Report 2020-2030

The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.

12 October 2020

READ

Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

02 October 2020

READ

Visiongain Publishes mRNA Vaccines Market Report 2021-2031

The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.

02 October 2020

READ

Categories